The ability to detect multiple compounds diagnostic of different inborn errors of metabolism in neo-natal dried blood specimens has enabled the rapid pace of development in the field of newborn screening. Following the success of the newborn screening market in phenylketonuria, experts in this field are optimistic that additional health benefits will emerge in the future.
Thus, advances in technology and the expansion of the uniform newborn screening panel of diseases have resulted in earlier life-saving treatment and intervention for at least 12,000 additional newborns with selected genetic, hearing, and endocrine disorders in the United States each year.
Technological advancements in tandem mass spectrometry, colorimetric analysis test, fluorescence analysis test, enzyme or liquid chromatography, and various immunological assays and other analyses, as well as a high adoption rate of newborn screening with new technology, are expected to drive market growth. Right Start, the world's first Integrated DNA testing for newborn screening to detect over 50 medical conditions, was launched in October 2018 by Life Cell International, India's leading stem cell bank and mother & baby diagnostics company.
Read more @ https://bit.ly/3mgKpNG
